NASDAQ:ADPT Adaptive Biotechnologies (ADPT) Stock Price, News & Analysis → Elon Musk’s Next Move Will Disrupt AI Forever (From InvestorPlace) (Ad) Free ADPT Stock Alerts $3.83 +0.33 (+9.43%) (As of 03:46 PM ET) Add Compare Share Share Today's Range$3.50▼$3.9350-Day Range$2.34▼$3.9952-Week Range$2.28▼$9.08Volume1.38 million shsAverage Volume1.60 million shsMarket Capitalization$564.43 millionP/E RatioN/ADividend YieldN/APrice Target$6.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Adaptive Biotechnologies alerts: Email Address Adaptive Biotechnologies MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside75.7% Upside$6.80 Price TargetShort InterestBearish8.17% of Shares Sold ShortDividend StrengthN/ASustainability-0.79Upright™ Environmental ScoreNews Sentiment0.36Based on 19 Articles This WeekInsider TradingSelling Shares$428,090 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.30) to ($1.09) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.85 out of 5 starsMedical Sector221st out of 925 stocksBiological Products, Except Diagnostic Industry27th out of 154 stocks 3.3 Analyst's Opinion Consensus RatingAdaptive Biotechnologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageAdaptive Biotechnologies has only been the subject of 3 research reports in the past 90 days.Read more about Adaptive Biotechnologies' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.17% of the outstanding shares of Adaptive Biotechnologies have been sold short.Short Interest Ratio / Days to CoverAdaptive Biotechnologies has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in Adaptive Biotechnologies has recently increased by 20.28%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAdaptive Biotechnologies does not currently pay a dividend.Dividend GrowthAdaptive Biotechnologies does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAdaptive Biotechnologies has received a 61.36% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Basic medical research services", "Scientific databases", and "Medical laboratory automation systems" products. See details.Environmental SustainabilityThe Environmental Impact score for Adaptive Biotechnologies is -0.79. Previous Next 2.4 News and Social Media Coverage News SentimentAdaptive Biotechnologies has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Adaptive Biotechnologies this week, compared to 3 articles on an average week.Search InterestOnly 13 people have searched for ADPT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows14 people have added Adaptive Biotechnologies to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adaptive Biotechnologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $428,090.00 in company stock.Percentage Held by InsidersOnly 5.20% of the stock of Adaptive Biotechnologies is held by insiders.Percentage Held by Institutions99.17% of the stock of Adaptive Biotechnologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Adaptive Biotechnologies' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Adaptive Biotechnologies are expected to grow in the coming year, from ($1.30) to ($1.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adaptive Biotechnologies is -2.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adaptive Biotechnologies is -2.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdaptive Biotechnologies has a P/B Ratio of 1.82. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Adaptive Biotechnologies' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceDoes this chart look familiar?Investors who understand when to get in — and when to get out… Can make a lot of money. Like in the chart, I showed you above…Get all the information here. About Adaptive Biotechnologies Stock (NASDAQ:ADPT)Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.Read More ADPT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADPT Stock News HeadlinesMay 10, 2024 | americanbankingnews.comHead-To-Head Survey: Replimune Group (NASDAQ:REPL) vs. Adaptive Biotechnologies (NASDAQ:ADPT)May 9, 2024 | finance.yahoo.comAdaptive Biotechnologies First Quarter 2024 Earnings: Beats ExpectationsMay 13, 2024 | InvestorPlace (Ad)Elon Musk’s Next Move Will Disrupt AI ForeverA revolutionary venture that is set to get rolled out by May 16. One well-connected Silicon Valley VC has uncovered a way for anybody to claim a stake in "Elon Musk's AI 2.0" with as little as $100.May 9, 2024 | americanbankingnews.comAdaptive Biotechnologies (NASDAQ:ADPT) Shares Gap Up Following Strong EarningsMay 9, 2024 | msn.comAdaptive Surf Championships return to Waikiki welcoming athletes from 18 countriesMay 8, 2024 | fool.comWhy Adaptive Biotechnologies Topped the Market TodayMay 8, 2024 | finance.yahoo.comAdaptive Biotechnologies Corporation (NASDAQ:ADPT) Q1 2024 Earnings Call TranscriptMay 8, 2024 | finance.yahoo.comAdaptive Biotechnologies Corp (ADPT) Q1 2024 Earnings Call Transcript Highlights: Strategic ...May 13, 2024 | InvestorPlace (Ad)Elon Musk’s Next Move Will Disrupt AI ForeverA revolutionary venture that is set to get rolled out by May 16. One well-connected Silicon Valley VC has uncovered a way for anybody to claim a stake in "Elon Musk's AI 2.0" with as little as $100.May 8, 2024 | msn.comADPT Stock Earnings: Adaptive Biotechnologies Beats EPS, Beats Revenue for Q1 2024May 7, 2024 | seekingalpha.comAdaptive Biotechnologies Corporation 2024 Q1 - Results - Earnings Call PresentationMay 7, 2024 | finance.yahoo.comAdaptive Biotechnologies: Q1 Earnings SnapshotMay 7, 2024 | markets.businessinsider.comAdaptive Biotechnologies Q1 Loss decreases, beats estimatesMay 7, 2024 | finance.yahoo.comAdaptive Biotechnologies Q1 2024 Earnings: Revenue Beats Estimates Amidst ChallengesMay 7, 2024 | globenewswire.comAdaptive Biotechnologies Reports First Quarter 2024 Financial ResultsMay 5, 2024 | americanbankingnews.comAdaptive Biotechnologies (ADPT) Set to Announce Earnings on TuesdayMay 1, 2024 | tmcnet.comHITRUST Enhances Cyber Threat Adaptive Engine Using Microsoft Azure OpenAI Service and Microsoft Defender Threat IntelligenceMay 1, 2024 | finance.yahoo.comNetenrich Launches Adaptive MDR™ for Google Chronicle Security Operations, Powered by Resolution Intelligence Cloud™ TechnologyApril 30, 2024 | msn.comUniversity of Arizona Adaptive Athletic Department receives $1 million donationApril 24, 2024 | msn.comFizik Antares Adaptive Reshapes Saddle that Started Fizik’s 3D-Printed Padding BoomApril 24, 2024 | finance.yahoo.comAdaptive Shield Launches Fast Forward Partner Program to Help Enterprises Secure the SaaS EcosystemApril 17, 2024 | globenewswire.comAdaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024April 16, 2024 | bizjournals.comAdaptive Biotechnologies names new CFO, restructures business linesApril 13, 2024 | msn.comAdaptive Foundation offers free fitness classes for veterans, first responders in TylerApril 9, 2024 | msn.comThe Center for Adaptive Riding hosts open house for new locationApril 4, 2024 | uk.investing.comAdaptive Biotechnologies CFO resigns, successor namedApril 2, 2024 | marketwatch.comAdaptive Biotechnologies to Restructure Businesses After ReviewSee More Headlines Receive ADPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adaptive Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today5/13/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ADPT CUSIPN/A CIK1478320 Webwww.constructionpartners.net Phone(206) 659-0067Fax206-659-0667Employees709Year Founded2009Price Target and Rating Average Stock Price Target$6.80 High Stock Price Target$10.00 Low Stock Price Target$5.00 Potential Upside/Downside+94.3%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-225,250,000.00 Net Margins-123.24% Pretax Margin-123.29% Return on Equity-56.58% Return on Assets-27.45% Debt Debt-to-Equity RatioN/A Current Ratio4.51 Quick Ratio4.50 Sales & Book Value Annual Sales$170.28 million Price / Sales3.03 Cash FlowN/A Price / Cash FlowN/A Book Value$1.86 per share Price / Book1.88Miscellaneous Outstanding Shares147,370,000Free Float139,705,000Market Cap$515.80 million OptionableOptionable Beta1.27 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMs. Julie Rubinstein (Age 52)President & COO Comp: $721.04kDr. Harlan S. Robins Ph.D. (Age 51)Co-Founder & Chief Scientific Officer Comp: $711.09kMs. Stacy L. Taylor (Age 64)Senior VP, General Counsel & Corporate Secretary Ms. Mary Pat LancelottaSenior Vice President of MRD BioPharmaKey CompetitorsTaysha Gene TherapiesNASDAQ:TSHAEditas MedicineNASDAQ:EDITC4 TherapeuticsNASDAQ:CCCCiTeos TherapeuticsNASDAQ:ITOSLexeo TherapeuticsNASDAQ:LXEOView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 102,134 shares on 5/10/2024Ownership: 8.733%Acadian Asset Management LLCBought 162,137 shares on 5/10/2024Ownership: 0.110%Pinnacle Wealth Planning Services Inc.Bought 14,438 shares on 5/10/2024Ownership: 0.010%Susquehanna Fundamental Investments LLCBought 22,096 shares on 5/7/2024Ownership: 0.015%Manchester Capital Management LLCBought 9,850 shares on 5/6/2024Ownership: 0.007%View All Insider TransactionsView All Institutional Transactions ADPT Stock Analysis - Frequently Asked Questions Should I buy or sell Adaptive Biotechnologies stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adaptive Biotechnologies in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ADPT shares. View ADPT analyst ratings or view top-rated stocks. What is Adaptive Biotechnologies' stock price target for 2024? 6 equities research analysts have issued 12 month price objectives for Adaptive Biotechnologies' shares. Their ADPT share price targets range from $5.00 to $10.00. On average, they predict the company's stock price to reach $6.80 in the next year. This suggests a possible upside of 75.7% from the stock's current price. View analysts price targets for ADPT or view top-rated stocks among Wall Street analysts. How have ADPT shares performed in 2024? Adaptive Biotechnologies' stock was trading at $4.90 on January 1st, 2024. Since then, ADPT stock has decreased by 21.0% and is now trading at $3.87. View the best growth stocks for 2024 here. When is Adaptive Biotechnologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our ADPT earnings forecast. How were Adaptive Biotechnologies' earnings last quarter? Adaptive Biotechnologies Co. (NASDAQ:ADPT) released its quarterly earnings data on Tuesday, May, 7th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.02. The business had revenue of $41.87 million for the quarter, compared to the consensus estimate of $38.78 million. Adaptive Biotechnologies had a negative net margin of 123.24% and a negative trailing twelve-month return on equity of 56.58%. Adaptive Biotechnologies's quarterly revenue was up 11.2% on a year-over-year basis. During the same quarter last year, the business posted ($0.40) EPS. What ETFs hold Adaptive Biotechnologies' stock? ETFs with the largest weight of Adaptive Biotechnologies (NASDAQ:ADPT) stock in their portfolio include ARK Genomic Revolution ETF (ARKG) and Amplify Treatments, Testing and Advancements ETF (GERM).First Trust Nasdaq Lux Digital Health Solutions ETF (EKG). What guidance has Adaptive Biotechnologies issued on next quarter's earnings? Adaptive Biotechnologies updated its first quarter 2024 earnings guidance on Tuesday, April, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $41.0 million-$43.0 million, compared to the consensus revenue estimate of $38.2 million. What is Chad Robins' approval rating as Adaptive Biotechnologies' CEO? 51 employees have rated Adaptive Biotechnologies Chief Executive Officer Chad Robins on Glassdoor.com. Chad Robins has an approval rating of 92% among the company's employees. This puts Chad Robins in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Adaptive Biotechnologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptive Biotechnologies investors own include NVIDIA (NVDA), Alibaba Group (BABA), QUALCOMM (QCOM), Johnson & Johnson (JNJ), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Home Depot (HD), Inovio Pharmaceuticals (INO), PayPal (PYPL) and Tesla (TSLA). When did Adaptive Biotechnologies IPO? Adaptive Biotechnologies (ADPT) raised $200 million in an IPO on Thursday, June 27th 2019. The company issued 12,500,000 shares at $15.00-$17.00 per share. Goldman Sachs, J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Guggenheim Securities, William Blair and BTIG were co-managers. Who are Adaptive Biotechnologies' major shareholders? Adaptive Biotechnologies' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.73%), Sumitomo Mitsui Trust Holdings Inc. (4.26%), Nikko Asset Management Americas Inc. (4.19%), Nordea Investment Management AB (0.58%), Essex Investment Management Co. LLC (0.19%) and Jennison Associates LLC (0.12%). Insiders that own company stock include Chad M Cohen, Chad M Cohen, Chad M Robins, Chad M Robins, Egon Durban, Euclidean Capital Llc, Francis Lo, Harlan S Robins, Harlan S Robins, Julie Rubinstein, Jyoti Palaniappan, Kyle Piskel, Lance Baldo, Michelle Renee Griffin, Nitin Sood, R Mark Adams, Stacy L Taylor and Tycho Peterson. View institutional ownership trends. How do I buy shares of Adaptive Biotechnologies? Shares of ADPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ADPT) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersDoes this make you sick?Allegiance GoldThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorThis 1 Biotech Stock has been shocking the marketsHuge AlertsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Crypto 9-5 Escape PlanCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptive Biotechnologies Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
